Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Silent PSMA/PSCA CAR-T in Prostate Cancer
NCT05732948Phase 1Unknown
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCTPSMA-PSCA in prostate cancer (PCa), sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. Primary endpoint: Tumor response at 8 weeks. Status: unknown.
02
Drugs
UCTPSMA-PSCA
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05732948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732948.